Century Therapeutics, Inc. (IPSC)

Over the past six months, Century Therapeutics' stock has been impacted by Q3 2025 earnings, price target decreases and increases, board member appointments and a resignation, a $135 million private placement, Piper Sandler's cash runway highlight, a rating downgrade to "Sell", and a significant stock price increase. Insider trading activity shows more stock was bought than sold.

As a clinical-stage biotechnology company without commercialized products, Century Therapeutics, Inc. has no demand seasonality. The company's revenue primarily stems from collaboration and licensing agreements.

Century Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic cell therapies for cancer and autoimmune diseases, utilizing iPSC technology to engineer NK and T cell candidates. The company's pipeline includes CNTY-813 for Type 1 Diabetes, CNTY-308 for B-cell-mediated autoimmune diseases and malignancies, CNTY-101 for B-cell-mediated autoimmune diseases, and solid tumor CAR iT programs.

Century Therapeutics is headquartered in Philadelphia, Pennsylvania, with operational and laboratory facilities. It also has a manufacturing facility in Branchburg, New Jersey, a laboratory in Hamilton, Ontario, focused on glioblastoma, and a Seattle-based innovation hub.

Century Therapeutics has a news sentiment score of 0.64, lower than the medical sector average. Short interest has increased by 148.05%, indicating decreased investor sentiment. The company has a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.71.

Century Therapeutics, Inc. has 83 institutional owners and shareholders holding a total of 20,952,222 shares. Aktiengesellschaft Bayer is the largest single shareholder, holding 14.67% of the company's shares. Institutions hold 50.20% of the stock, while insiders hold 4.37%.